Effect of Genetic Variants of CCR2 and CCL2 on the Natural History of HIV-1 Infection
Consuelo Viladés(Hospital Universitario Fundación Jiménez Díaz), Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Enric Pedrol(Hospital General de Granollers), Josep M. Gatell(Hospital Clínic de Barcelona), Hernando Knobel(Hospital General de Granollers), Cristina Gutiérrez(Hospital Universitari Joan XXIII de Tarragona), Montserrat Broch(Hospital Universitari Joan XXIII de Tarragona), Carlos Alonso‐Villaverde(Institut de Recerca Biomèdica Catalunya Sud), Cristóbal Richart(Universitat Rovira i Virgili), Peré Domingo(Hospital de Sant Pau), Felipe García(Apple (Israel)), David Dalmau(University Hospital Mútua de Terrassa), Montserrat Plana(Universitat de Barcelona), Montserrat Olona(Institut de Recerca Biomèdica Catalunya Sud), Ma Antònia Sambeat(Universitat Autònoma de Barcelona), Joaquim Peraire(Instituto de Salud Carlos III), Anna Lena Lopez(Universitat de Barcelona)
Cited by 20
Related Papers
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
|Proceedings of the National Academy of Sciences|2022|198
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143